Unrelated SCT induces long-term remission in patients with blastic plasmacytoid dendritic cell neoplasm

Bone Marrow Transplantation

Volumn 48, Issue 6, 2013, Pages 799-802

  Unteregger, M ^a   Valentin, A ^a   Zinke Cerwenka, W ^a   Troppan, K ^a   Deutsch, A ^a   Cerroni, L ^a   Linkesch, W ^a   Neumeister, P ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

ASCT; blastic plasmacytoid DC neoplasm; reduced intensity conditioning; umbilical cord blood transplantation

Indexed keywords

BRENTUXIMAB VEDOTIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; MELPHALAN; NAVELBINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLASSICAL HODGKIN LYMPHOMA; CLINICAL ARTICLE; COMORBIDITY; CORD BLOOD STEM CELL TRANSPLANTATION; DENDRITIC CELL SARCOMA; DISEASE FREE SURVIVAL; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PLASMABLASTIC LYMPHOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; UNRELATED DONORS; WHOLE BODY RADIATION;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS LEUKEMIA EFFECT; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASMS, PLASMA CELL; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

EID: 84879075642     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.242     Document Type: Article

References (18)

1. Facchetti F, Ungari M, Marocolo D, Lonardi S, Vermi W. Blastic plasmacytoid dendritic cell neoplasm. Hematology Meeting Reports (formerly Haematologica Reports) 2009; 3: 1-3.
2. Petrella T, Bagot M, Willemze R, Beylot-Barry M, Vergier B, Delaunay M et al. Blastic NK-cell lymphomas (agranular CD4\+ CD56\+ hematodermic neoplasms). Am J Clin Pathol 2005; 123: 662.
3. Garnache-Ottou F, Feuillard J, Saas P. Plasmacytoid dendritic cell leukaemia/lymphoma: towards a well defined entity? Br J Haematol 2007; 136: 539-548.
4. Jegalian AG, Buxbaum NP, Facchetti F, Raffeld M, Pittaluga S, Wayne AS et al. Blastic plasmacytoid dendritic cell neoplasm in children: diagnostic features and clinical implications. Haematologica 2010; 95: 1873-1879.
5. Cota C, Vale E, Viana I, Requena L, Ferrara G, Anemona L et al. Cutaneous manifestations of blastic plasmacytoid dendritic cell neoplasm-morphologic and phenotypic variability in a series of 33 patients. Am J Surg Pathol 2010; 34: 75-87.
6. Dalle S, Beylot-Barry M, Bagot M, Lipsker D, Machet L, Joly P et al. Blastic plasmacytoid dendritic cell neoplasm: is transplantation the treatment of choice? Br J Dermatol 2010; 162: 74-79.
7. Reimer P, Rüdiger T, Kraemer D, Kunzmann V, Weissinger F, Zettl A et al. What is CD4\+CD56\+ malignancy and how should it be treated? Bone Marrow Transplant 2003; 32: 637-646.
8. Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM et al. Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity. Biol Blood Marrow Transplant 2011; 17: 1250-1254.
9. Krishnan S, Tan D, Hwang WYK. Treatment of blastic plasmacytoid dendritic cell neoplasms with cord blood transplants. Clin Adv Hematol Oncol 2011; 9: 569-570.
10. Linkesch W, Weger M, Eder I, Auner HW, Pernegg C, Kraule C et al. Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP). Eur J Drug Metab Pharmacokinet 2001; 26: 179-184.
11. Duff JM, Rossi ML, Fromm J, Hsu JW. A 21-year-old woman with blastic nk cell leukemia/lymphoma who achieved durable remission with hypercvad and unrelated umbilical cord blood transplant. Clin Adv Hematol Oncol 2011; 9: 566-568.
12. Kantarjian HM, O'Brien S, Smith TL, Cortes J, Giles FJ, Beran M et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18: 547-561.
13. Trappe R, Oertel S, Leblond V, Mollee P, Sender M, Reinke P et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell posttransplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13: 196-206.
14. Ham JC, Janssen JJWM, Boers JE, Kluin PM, Verdonck LF. Allogeneic stem-cell transplantation for blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol 2012; 30: e102-e103.
15. Kaloyannidis P, Zomas A, Paterakis G, Vadikoliou C, Mallouri D, Sakkas L et al. GVL effect in plasmacytoid DC leukemia/lymphoma. Bone Marrow Transplant 2010; 45: 961-961.
16. Barker JN, Martin PL, Coad JE, DeFor T, Trigg ME, Kurtzberg J et al. Low incidence of Epstein-Barr virus-associated posttransplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001; 7: 395-399.
17. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang M-J, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
18. Brunstein CG, Weisdorf DJ, Defor T, Barker JN, Tolar J, van Burik J-AH et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 2006; 108: 2874-2880.